Type 2 Diabetes – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Type 2 diabetes is a chronic and progressive metabolic disorder, typically irreversible, characterized by impaired metabolism of carbohydrates, fats, and proteins due to insufficient or ineffective use of the hormone insulin. Three core pathophysiological processes contribute to the development of type 2 diabetes: insulin resistance, defective insulin secretion, and excessive hepatic glucose production. This results in hyperglycemia, prompting increased insulin production, followed by a decline in the function and mass of pancreatic beta cells, ultimately leading to diabetes. In the majority of diabetic and prediabetic individuals, a high body mass index (BMI > 30) is a crucial predisposing factor for the onset of type 2 diabetes. There is a close association between the prevalence of insulin resistance and obesity. Vascular inflammation arising from hyperglycemia plays a pivotal role in the emergence of complications during late-stage diabetes, affecting both macro- and microvasculature and contributing to conditions such as retinopathy, neuropathy, nephropathy, and cardiovascular disease. Women, especially those with obesity, carry a more significant risk factor burden at the time of their type 2 diabetes diagnosis, with psychosocial stress potentially playing a more prominent role in diabetes risk for women. Additionally, pregnancies can unveil pre-existing metabolic abnormalities, leading to the diagnosis of gestational diabetes, a significant risk factor for progressing to type 2 diabetes in women. Gender differences exist in the context of type 2 diabetes and other cardiovascular risk factors, affecting comorbidities, the manifestation of complications, and the initiation and adherence to therapy. Women diagnosed with type 2 diabetes exhibit a greater relative risk of cardiovascular disease (CVD) and mortality compared to men. While the prevalence of type 2 diabetes mellitus is increasing in both sexes, men are typically diagnosed at a younger age and with lower body fat mass than women.

·       In the USA, the prevalence rate of type 2 diabetes varies from 8.5% to 11.8% of the population, with approximately 78% of the prevalent population receiving treatment.

 

Thelansis’s “Type 2 Diabetes Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Type 2 Diabetes treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Type 2 Diabetes across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Type 2 Diabetes Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Type 2 Diabetes – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Type 2 Diabetes, Type 2 Diabetes market outlook, Type 2 Diabetes competitive landscape, Type 2 Diabetes market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)